Stock Track | Omnicell Plunges 5.39% in Pre-Market as Q4 Earnings Disappoint Despite Revenue Beat

Stock Track

02-06

Omnicell Inc. (OMCL) shares plummeted 5.39% in pre-market trading on Thursday, following the company's mixed fourth quarter 2024 results reported after the market close on Wednesday.

For the quarter ended December 31, 2024, the medication management solutions provider posted earnings of $0.34 per share, missing the consensus estimate of $0.57 per share. However, revenue came in at $306.9 million, surpassing analysts' expectations of $296.9 million.

While Omnicell delivered strong revenue growth of 19% year-over-year, driven by improved macroeconomic conditions and timing of XT Series system implementations, higher costs weighed on profitability. The company cited increased expenses related to investments in generative AI, autonomous driving technologies, and other growth initiatives.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1191708832"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1191708832\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1191708832?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-06 21:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1191708832","market":"us","top_or_hot":-1,"title":"Stock Track | Omnicell Plunges 5.39% in Pre-Market as Q4 Earnings Disappoint Despite Revenue Beat","media":"Stock Track","content":"<p>Omnicell Inc. (OMCL) shares plummeted 5.39% in pre-market trading on Thursday, following the company's mixed fourth quarter 2024 results reported after the market close on Wednesday.</p>\n\n<p>For the quarter ended December 31, 2024, the medication management solutions provider posted earnings of $0.34 per share, missing the consensus estimate of $0.57 per share. However, revenue came in at $306.9 million, surpassing analysts' expectations of $296.9 million.</p>\n\n<p>While Omnicell delivered strong revenue growth of 19% year-over-year, driven by improved macroeconomic conditions and timing of XT Series system implementations, higher costs weighed on profitability. The company cited increased expenses related to investments in generative AI, autonomous driving technologies, and other growth initiatives.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Omnicell Plunges 5.39% in Pre-Market as Q4 Earnings Disappoint Despite Revenue Beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Omnicell Plunges 5.39% in Pre-Market as Q4 Earnings Disappoint Despite Revenue Beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-06 21:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Omnicell Inc. (OMCL) shares plummeted 5.39% in pre-market trading on Thursday, following the company's mixed fourth quarter 2024 results reported after the market close on Wednesday.</p>\n\n<p>For the quarter ended December 31, 2024, the medication management solutions provider posted earnings of $0.34 per share, missing the consensus estimate of $0.57 per share. However, revenue came in at $306.9 million, surpassing analysts' expectations of $296.9 million.</p>\n\n<p>While Omnicell delivered strong revenue growth of 19% year-over-year, driven by improved macroeconomic conditions and timing of XT Series system implementations, higher costs weighed on profitability. The company cited increased expenses related to investments in generative AI, autonomous driving technologies, and other growth initiatives.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OMCL","symbol_name":"Omnicell","start_time":0,"source_url":"","article_id":"1191708832","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1191708832","pubTimestamp":1738849486,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Omnicell Inc.  shares plummeted 5.39% in pre-market trading on Thursday, following the company's mixed fourth quarter 2024 results reported after the market close on Wednesday.For the quarter ended December 31, 2024, the medication management solutions provider posted earnings of $0.34 per share, missing the consensus estimate of $0.57 per share. However, revenue came in at $306.9 million, surpassing analysts' expectations of $296.9 million.While Omnicell delivered strong revenue growth of 19% y","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"OMCL":"Omnicell"},"translate_title":"尽管营收超出预期，但第四季度盈利令人失望，Omnicell盘前暴跌5.39%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OMCL":1},"content_text":"Omnicell Inc. (OMCL) shares plummeted 5.39% in pre-market trading on Thursday, following the company's mixed fourth quarter 2024 results reported after the market close on Wednesday.\nFor the quarter ended December 31, 2024, the medication management solutions provider posted earnings of $0.34 per share, missing the consensus estimate of $0.57 per share. However, revenue came in at $306.9 million, surpassing analysts' expectations of $296.9 million.\nWhile Omnicell delivered strong revenue growth of 19% year-over-year, driven by improved macroeconomic conditions and timing of XT Series system implementations, higher costs weighed on profitability. The company cited increased expenses related to investments in generative AI, autonomous driving technologies, and other growth initiatives.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1}}}